MedTrace Logo

A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT05336266 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-01-06

No results posted yet for this study

Summary

The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.

Conditions

Interventions

DRUG

Ketorolac Tromethamine

Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days

Sponsors & Collaborators

  • Yinuoke Ltd.

    collaborator UNKNOWN

  • Andrew Hendifar, MD

    lead OTHER

Principal Investigators

  • Andrew Hendifar, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-02-19
Completion
2026-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05336266 on ClinicalTrials.gov